Cumberland to File Rolling NDA for Ifetroban in DMD Cardiomyopathy Despite FDA Efficacy Concerns
CPIX has more than doubled off its 52-week low of $1.85 on elevated volume (4.9× avg).
Summary
Cumberland will submit a rolling NDA for ifetroban in DMD cardiomyopathy, betting a Phase 2 trial plus natural-history data can win Traditional Approval without a Phase 3 — even though the FDA questioned whether that package proves efficacy.
Key Events · Product Development and Regulatory · CPIX
-
Rolling NDA Planned for Ifetroban
Cumberland will submit an NDA for ifetroban in DMD cardiomyopathy as a Traditional Approval, using the 12-month Phase 2 FIGHT DMD trial plus two natural-history databases as the pivotal package instead of a Phase 3.
-
FDA Flags Efficacy Evidence Gap
At the pre-NDA meeting the FDA questioned whether the data package meets the substantial-evidence standard and asked for additional analysis, citing the LVEF endpoint, comparator issues and the statistical analysis plan.
-
Rolling Review Granted
The FDA granted Cumberland's request for rolling review, letting completed NDA sections be submitted for review before the full application is filed.
-
Phase 2 Efficacy and Safety Data
High-dose ifetroban produced a statistically significant 5.4% absolute LVEF improvement (p=0.002) versus the combined placebo and matched natural-history control, with no treatment-related serious adverse events through up to 36 months.
Analysis · CPIX · Life Sciences
Cumberland is taking ifetroban straight to a Traditional Approval NDA using the 12-month Phase 2 FIGHT DMD trial plus natural-history comparators, skipping the Phase 3 the FDA suggested. The FDA granted rolling review, which lets sections be filed piecemeal, but it also said it is not convinced the package provides substantial evidence of efficacy and asked for more analysis. That is the whole bet: approval would validate a drug with Orphan Drug, Rare Pediatric Disease and Fast Track designations and no approved competitor for DMD-related heart disease; a refusal-to-file or a demand for a Phase 3 would push the timeline out by years and require substantial additional capital — a real constraint with only $3.9M of cash reported at the last quarter-end before the $100M Apotex proceeds. The 5.4% absolute LVEF improvement (p=0.002) and clean long-term safety through 36 months are the supporting evidence, but the FDA's stated doubts about the LVEF endpoint, the comparator and the statistical analysis plan are the risk that decides the outcome.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPIX was trading at $5.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.2M. The 52-week trading range was $1.85 to $9.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.